CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- PositionOperating margin is -102.9%, lower than 95% of its Medical Devices peers (median 8.1%)
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
447.27MUSDvs all stocks (USD)
Revenue (TTM)
160.03MUSDvs all stocks (USD)
Profit Margin
-80.34%vs Medical Devices peers
Beta
2.29xvs all stocks
52-Week Change
-0.69%vs all stocks
Market Capitalization
447.27MUSDvs all stocks (USD)
Enterprise Value
877.69MUSDvs all stocks (USD)
Forward P/E
-3.63xvs Medical Devices peers
Price to Sales (TTM)
2.79xvs Medical Devices peers
Price to Book (MRQ)
180.00xvs Medical Devices peers
Enterprise to Revenue
5.49xvs Medical Devices peers
Enterprise to EBITDA
-6.13xvs Medical Devices peers
Gross Margin
34.54%vs Medical Devices peers
Profit Margin
-80.34%vs Medical Devices peers
Operating Margin
-102.89%vs Medical Devices peers
Return on Assets (TTM)
-11.96%vs Medical Devices peers
Return on Equity (TTM)
-273.55%vs Medical Devices peers
Revenue (TTM)
160.03MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.5300USDUpdated Jul 19, 2026Quarterly Revenue Growth
0.10%vs Medical Devices peers
Gross Profit (TTM)
61.33MUSDvs all stocks (USD)
EBITDA (TTM)
-143.15MUSDvs all stocks (USD)
Net Income (TTM)
-128.58MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
0.07%vs Medical Devices peers
Operating Cash Flow (TTM)
-111.84MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-48.24MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Revenue
160.00MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
114.22MUSDFY2025 · Dec 31, 2025Gross Profit
45.78MUSDFY2025 · Dec 31, 2025Operating Income
-557.56MUSDvs all stocks (USD)
Pre-tax Income
-546.06MUSDFY2025 · Dec 31, 2025Income Tax Expense
318.00KUSDFY2025 · Dec 31, 2025Net Income
-546.38MUSDFY2025 · Dec 31, 2025EBIT
-539.10MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-156.39MUSDFY2025 · Dec 31, 2025Research & Development
97.31MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
141.49MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
6.95MUSDFY2025 · Dec 31, 2025EPS (Basic)
-1.82USDFY2025 · Dec 31, 2025EPS (Diluted)
-1.82USDFY2025 · Dec 31, 2025Basic Shares Outstanding
299.96MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
299.96MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-546.38MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-143.08MUSDFY2025 · Dec 31, 2025Free Cash Flow
-145.80MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
65.26MUSDFY2025 · Dec 31, 2025Interest Paid
8.26MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-546.38MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
386.41MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
-546.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
41.67MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-17.01MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-7.92MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
2.48MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-1.79MUSDFY2025 · Dec 31, 2025Capital Expenditures
-2.71MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-5.00MUSDFY2025 · Dec 31, 2025Net Acquisitions
0.00USDFY2025 · Dec 31, 2025Purchase of Investments
-216.91MUSDFY2025 · Dec 31, 2025Sale of Investments
340.07MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
120.45MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
0.00USDFY2025 · Dec 31, 2025Net Financing Cash Flow
0.00USDFY2025 · Dec 31, 2025Shares Outstanding
310.49MSharesUpdated Jul 19, 2026Float Shares
303.83MSharesUpdated Jul 19, 2026Shares Short
47.49MSharesUpdated Jul 19, 2026Short Ratio
7.15daysvs all stocks
Short % of Shares Outstanding
17.58%vs all stocks
% Held by Insiders
8.77%vs all stocks
% Held by Institutions
53.82%vs all stocks
Total Cash (MRQ)
275.96MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.8880USDUpdated Jul 19, 2026Total Debt (MRQ)
706.39MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
298.56xvs Medical Devices peers
Current Ratio (MRQ)
5.65xvs Medical Devices peers
Book Value per Share (MRQ)
0.0080USDUpdated Jul 19, 2026Total Assets
784.08MUSDvs all stocks (USD)
Total Current Assets
375.05MUSDFY2025 · Dec 31, 2025Total Liabilities
778.73MUSDFY2025 · Dec 31, 2025Total Non-current Assets
409.03MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
705.90MUSDFY2025 · Dec 31, 2025Total Current Liabilities
72.83MUSDFY2025 · Dec 31, 2025Cash
60.50MUSDFY2025 · Dec 31, 2025Cash Equivalents
3.21MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
63.71MUSDFY2025 · Dec 31, 2025Other Short-term Investments
215.80MUSDFY2025 · Dec 31, 2025Accounts Receivable
35.45MUSDFY2025 · Dec 31, 2025Inventory
49.28MUSDFY2025 · Dec 31, 2025Accounts Payable
20.77MUSDFY2025 · Dec 31, 2025Short-term Debt
448.00KUSDFY2025 · Dec 31, 2025Deferred Revenue
15.94MUSDFY2025 · Dec 31, 2025Other Current Liabilities
654.00KUSDFY2025 · Dec 31, 2025Long-term Debt
701.97MUSDFY2025 · Dec 31, 2025Common Stock (Book)
302.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-2.70BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
5.35MUSDvs all stocks (USD)
52-Week Low
1.09USDUpdated Jul 19, 202652-Week High
2.73USDUpdated Jul 19, 202652-Week Change
-0.69%vs all stocks
Beta
2.29xvs all stocks
50-Day MA
1.44USDUpdated Jul 19, 2026200-Day MA
1.71USDUpdated Jul 19, 2026Avg 10-Day Volume
4.76MSharesUpdated Jul 19, 2026Avg 30-Day Volume
5.81MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-0.4100USDUpdated Jul 19, 2026Other Income / Expense
18.46MUSDFY2025 · Dec 31, 20253 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
Where is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is -102.9%, lower than 95% of its Medical Devices peers (median 8.1%)Significant
Operating margin: -1.03Industry median: 0.08Industry P5: -0.73Peers compared: 102
Return on equity is -273.6%, lower than 95% of its Medical Devices peers (median 3%)Significant
Return on equity: -2.74Industry median: 0.03Industry P5: -0.69Peers compared: 102
Debt-to-equity is 298.56×, higher than 95% of its Medical Devices peers (median 0.11×)Significant
Debt-to-equity: 298.558Industry median: 0.11Industry P95: 1.20Peers compared: 102
Price-to-book is 180×, higher than 95% of its Medical Devices peers (median 2.69×)Significant
Price-to-book: 180Industry median: 2.69Industry P95: 16.17Peers compared: 102
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Zhejiang Haisen Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Honz Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Jw Pharmaceutical Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shoulder Innovations, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cybin Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Varex Imaging Corporation
Tier 1ProductionApproval-Gated PipelineRule
Rezolute, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Clover Biopharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Delcath Systems Inc.
Tier 1ProductionApproval-Gated PipelineRule
Baotou Dongbao Bio-Tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Veritone, Inc.
3 interpretationsHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBCUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And Drawdown
Draganfly Inc.
3 interpretationsHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBCUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And Drawdown
Wave Life Sciences Ltd.
3 interpretationsHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBCUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And Drawdown